These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18175250)

  • 1. Therapeutic approaches for Alzheimer's disease.
    Jahnke U
    IDrugs; 2008 Jan; 11(1):4-6. PubMed ID: 18175250
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: which therapeutic perspectives?].
    Checler F; Buée L
    Ann Pharm Fr; 2009 Mar; 67(2):136-53. PubMed ID: 19298897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and processing of pathologic proteins in Alzheimer's disease.
    Anderton BH
    Hippocampus; 1993; 3 Spec No():227-37. PubMed ID: 8287100
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dementia, Alzheimer's disease, Abeta peptide and tau protein].
    Duyckaerts C; He Y; Seilhean D; Hauw JJ
    Ann Pathol; 1995; 15(1):6-10. PubMed ID: 7702671
    [No Abstract]   [Full Text] [Related]  

  • 5. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
    Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
    Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tombstone in Alzheimer's?
    Mattson MP; Carney JW; Butterfield DA
    Nature; 1995 Feb; 373(6514):481. PubMed ID: 7845457
    [No Abstract]   [Full Text] [Related]  

  • 7. [The mechanisms of pathogenesis in Alzheimer's disease].
    Li L
    Sheng Li Ke Xue Jin Zhan; 1998 Oct; 29(4):345-8. PubMed ID: 12501666
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tau aggregation inhibitors for Alzheimer's disease.
    Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
    Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgens and Alzheimer's disease.
    Drummond ES; Harvey AR; Martins RN
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):254-9. PubMed ID: 19373081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cholesterol metabolic disorders and Alzheimer's disease].
    Hao JW; Li L
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):64-6. PubMed ID: 15881350
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in Alzheimer's disease drug discovery: an update.
    Williams M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
    Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
    Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
    Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
    Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular and cellular pathogenesis of dementia of the Alzheimer's type an overview.
    Luque FA; Jaffe SL
    Int Rev Neurobiol; 2009; 84():151-65. PubMed ID: 19501717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The shorter amyloid cascade hypothesis.
    Hardy J
    Neurobiol Aging; 1999; 20(1):85; discussion 87. PubMed ID: 10466899
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring the amyloid beta-peptide in vivo--caveat emptor.
    Thompson PW; Lockhart A
    Drug Discov Today; 2009 Mar; 14(5-6):241-51. PubMed ID: 19135168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which is a better target for AD immunotherapy, A beta or tau?
    Martin-Jones Z; Lasagna-Reeves C
    Alzheimer Dis Assoc Disord; 2008; 22(2):111-2. PubMed ID: 18525281
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy.
    Margittai M; Langen R
    Q Rev Biophys; 2008; 41(3-4):265-97. PubMed ID: 19079806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.